[go: up one dir, main page]

WO2003039444B1 - Topikale verwendung von cytokinen und/oder chemokinen zur behandlung von viralen oder mykotischen hauterkrankungen oder tumorerkrankungen - Google Patents

Topikale verwendung von cytokinen und/oder chemokinen zur behandlung von viralen oder mykotischen hauterkrankungen oder tumorerkrankungen

Info

Publication number
WO2003039444B1
WO2003039444B1 PCT/EP2002/012438 EP0212438W WO03039444B1 WO 2003039444 B1 WO2003039444 B1 WO 2003039444B1 EP 0212438 W EP0212438 W EP 0212438W WO 03039444 B1 WO03039444 B1 WO 03039444B1
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
chemokines
skin diseases
use according
cytokines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/012438
Other languages
English (en)
French (fr)
Other versions
WO2003039444A3 (de
WO2003039444A2 (de
Inventor
John Nieland
Christoph Rehfuess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medigene AG
Original Assignee
Medigene AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene AG filed Critical Medigene AG
Priority to CA002474196A priority Critical patent/CA2474196A1/en
Priority to JP2003541736A priority patent/JP2005512989A/ja
Priority to EP02796544A priority patent/EP1441755A2/de
Priority to US10/493,884 priority patent/US20050008614A1/en
Publication of WO2003039444A2 publication Critical patent/WO2003039444A2/de
Publication of WO2003039444A3 publication Critical patent/WO2003039444A3/de
Publication of WO2003039444B1 publication Critical patent/WO2003039444B1/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ein Gegenstand der Erfindung ist die Verwendung mindestens eines Cytokines und/oder Chemokines zur Herstellung eines topikal wirkenden Arzneimittels zur Behandlung von viralen und/oder mykotischen Hauterkrankungen und/oder Tumorerkrankungen.

Claims

GEÄNDERTE ANSPRÜCHE[beim Internationalen Büro am 24. Juli 2003 (24.07.03) eingegangen; ursprünglicher Anspruch 1 ersetzt durch geänderten Anspruch 1 ; sonstige Ansprüche 2-13 unverändert]
1. Verwendung mindestens eines Cytokines und/oder Chemokines zur Herstellung eines topikal wirkenden Arzneimittels zur Behandlung von Hauterkrankungen verursacht von mindestens einem Papilloma Virus und/oder mindestens einem Herpes Virus, von mykotischen Hauterkrankungen und/oder von Neoplasien des Genital- und Analtraktes.
2. Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass das Arzneimittel mehr als drei, insbesondere drei, vorzugsweise zwei Cytokine und/oder Chemokine enthält.
3. Verwendung nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass das Arzneimittel im wesentlichen keine antigen-wirkenden Bestandteile enthält.
4. Verwendung nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass das Cytokin und/oder Chemokin GM-CSF, G-CSF, IL1, LL2, LL3, IL4, LL5, 3X6, IL7, 3X8, LL9, JX10, IL11, JX12, JX13, T 14, IL15, 3X16, B 17, IL18, 3X19, 3X20, 3X21, 3X22, IFNα, 3PNß, 3PNγ, Flt3 L, Flt3, 1RANTES,
Mfflα, MlPlß, MJPlγ, MTPlδ, MIP2, MIP2α, MIP2ß, MIP3 , MIP3ß, MTP4, MJP5, MCP1, MCPlß, MCP2, MCP3, MCP4, MCP5, MCP6, öcykine, Dcckl und/oder DCDF, insbesondere GM-CSF, ILANTES und/oder MlPlα ist.
5. Verwendung nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass die viralen Hauterkrankungen und/oder Tumorerkrankungen
PCT/EP2002/012438 2001-11-07 2002-11-07 Topikale verwendung von cytokinen und/oder chemokinen zur behandlung von viralen oder mykotischen hauterkrankungen oder tumorerkrankungen Ceased WO2003039444A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002474196A CA2474196A1 (en) 2001-11-07 2002-11-07 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
JP2003541736A JP2005512989A (ja) 2001-11-07 2002-11-07 ウイルス性または真菌性の皮膚病または腫瘍疾患の処置のためのサイトカインおよびケモカインの局所使用
EP02796544A EP1441755A2 (de) 2001-11-07 2002-11-07 Topikale verwendung von cytokinen und/oder chemokinen zur behandlung von viralen oder mykotischen hauterkrankungen oder tumorerkrankungen
US10/493,884 US20050008614A1 (en) 2001-11-07 2002-11-07 Topical use of cytokines and chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10154579A DE10154579A1 (de) 2001-11-07 2001-11-07 Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
DE10154579.7 2001-11-07

Publications (3)

Publication Number Publication Date
WO2003039444A2 WO2003039444A2 (de) 2003-05-15
WO2003039444A3 WO2003039444A3 (de) 2003-11-13
WO2003039444B1 true WO2003039444B1 (de) 2003-12-18

Family

ID=7704851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/012438 Ceased WO2003039444A2 (de) 2001-11-07 2002-11-07 Topikale verwendung von cytokinen und/oder chemokinen zur behandlung von viralen oder mykotischen hauterkrankungen oder tumorerkrankungen

Country Status (6)

Country Link
US (1) US20050008614A1 (de)
EP (1) EP1441755A2 (de)
JP (1) JP2005512989A (de)
CA (1) CA2474196A1 (de)
DE (1) DE10154579A1 (de)
WO (1) WO2003039444A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342980T1 (de) 2000-08-08 2006-11-15 Zymogenetics Inc Lösliche zcyctor 11 cytokinrezeptoren
CA2422033A1 (en) 2000-09-15 2002-03-21 Zymogenetics, Inc. Method for treating inflammation
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US20040086908A1 (en) 2002-03-07 2004-05-06 Chandrasekher Yasmin A. Soluble heterodimeric cytokine receptor
EP1977760A3 (de) * 2001-12-17 2009-11-04 ZymoGenetics, Inc. Verfahren zur Behandlung von Infektionen durch Humanes Papilloma Virus (HPV)
CA2519057A1 (en) 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
EP2143733A1 (de) 2003-11-21 2010-01-13 ZymoGenetics, Inc. Anti-il-20-Rezeptor-Antikörper und Bindungspartner und Verfahren zur Anwendung bei Entzündungen
SE0400942D0 (sv) * 2004-04-08 2004-04-08 Henrik Arnberg Composition and method
US20130205723A1 (en) * 2004-09-15 2013-08-15 Cummins-Allison Corp. System, method and apparatus for automatically filling a coin cassette
CA2584157C (en) 2004-10-22 2014-10-14 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
US20060182724A1 (en) * 2005-02-15 2006-08-17 Riordan Neil H Method for expansion of stem cells
CN100403687C (zh) 2005-03-29 2008-07-16 华为技术有限公司 在多协议标签交换网络中实现分域管理和保护的方法
EP2139447A2 (de) 2007-03-20 2010-01-06 Harold Brem Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
WO2009070639A1 (en) 2007-11-28 2009-06-04 Irx Therapeutics, Inc. Method of increasing immunological effect
MX2011012147A (es) 2009-05-15 2012-06-19 Irx Therapeutics Inc Inmunoterapia de vacuna.
US9333238B2 (en) 2009-12-08 2016-05-10 Irx Therapeutics, Inc. Method of immunotherapy for treament of human papillomavirus infection
JP6295458B2 (ja) * 2013-03-08 2018-03-20 たいまつ食品株式会社 顆粒球コロニー刺激因子産出誘導・促進用産物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
AU1462392A (en) * 1991-02-22 1992-09-15 Amgen, Inc. Use of gm-csf and g-csf to promote accelerated wound healing
WO1993025228A1 (en) * 1992-06-15 1993-12-23 Whittier Institute For Diabetes And Endocrinology Cytotoxins specific for gm-csf receptor-bearing cells
JP2001515869A (ja) * 1997-09-11 2001-09-25 アメリカ合衆国 粘膜の細胞障害性ｔリンパ球応答
EP1030680A4 (de) * 1998-09-15 2003-05-02 Genetics Inst Behandlung von kaposisarkom mit il-12

Also Published As

Publication number Publication date
WO2003039444A3 (de) 2003-11-13
EP1441755A2 (de) 2004-08-04
CA2474196A1 (en) 2003-05-15
WO2003039444A2 (de) 2003-05-15
JP2005512989A (ja) 2005-05-12
US20050008614A1 (en) 2005-01-13
DE10154579A1 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
WO2003039444B1 (de) Topikale verwendung von cytokinen und/oder chemokinen zur behandlung von viralen oder mykotischen hauterkrankungen oder tumorerkrankungen
KR102026535B1 (ko) 생약 추출 혼합물을 포함하는 화장료 조성물
DE3856516T2 (de) Verwendung von rekombinantem koloniestimulierendem Faktor-1 zur Herstellung eines Medikaments gegen Cytomegalovirusinfektionen
Morinaga et al. An in vivo Study of Hepatic and Splenic Interleukin‐lβ mRNA Expression Following Oral PSK or LEM Administration
ATE74272T1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
DE69001686T2 (de) Behandlung von leukozytstoerungen mit gm-csf.
RU2003104525A (ru) Применение штаммов вируса parapox ovis для получения антивирусных и противораковых лекарственных средств
EP0242553A1 (de) Verwendung von Allantoin und Schwefel für die Herstellung pharmazeutischer Zusammensetzungen in der Behandlung von Zahn-/Mundkrankheiten
Shen et al. Erythropoietin attenuates white matter damage, proinflammatory cytokine and chemokine induction in developing rat brain after intra‐uterine infection
Lu et al. Anti‐tumor effects of recombinant human macrophage colony‐stimulating factor, alone or in combination with local irradiation, in mice inoculated with Lewis lung carcinoma cells
DE69332576T2 (de) Glykolisierte Cytokine
Braunschweiger et al. Interleukin-1α-induced tumour pathophysiologies can be exploited with bioreductive alkylating agents
CN104491083B (zh) 一种治疗宠物皮肤病的药浴制剂及其制备方法
Bester, RC* & Coetzer A chronic wasting syndrome in a horse associated with granulomatous enteritis
DE69126977T2 (de) Verwendung von Leukoregulin zur Behandlung von mit einem envelope-Virus infizierten Tier
JPH06509057A (ja) 促進された創傷治癒
Irving Macrophages in the periodontal tissues of rats' incisor teeth
CN116509849B (zh) 雷帕霉素在制备辅助治疗咖啡斑药物中的应用
Szöke Condyloma acuminatum treated with human leukocyte interferon
RU2246974C1 (ru) Способ лечения рецидивирующего бронхита у детей
JPS6013004B2 (ja) インタ−フエロン誘起剤の製法
DE4435661C2 (de) Mittel zur Behandlung von Papillomvirus-positiven gutartigen, malignen und prämalignen Läsionen
EP1163903B1 (de) Methanal - Injektion zur Behandlung epidemischer Tierkrankheiten
CN117982579A (zh) 一种用于治疗湿疹类皮肤病的药物组合物及其制备方法
RU96103216A (ru) Средство для лечения термических поражений кожи, трофических язв, пролежней и длительно незаживающих ран

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Free format text: 20030724

WWE Wipo information: entry into national phase

Ref document number: 2002796544

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002362204

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003541736

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002796544

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2474196

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10493884

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002796544

Country of ref document: EP